secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001104659-24-129823
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax amends Australia COVID vaccine agreement; cancels doses, credits $31M, extends to 2029
--------------------------------------------------------------------------------

- Amendment #5 cancels certain COVID vaccine doses scheduled for delivery Q4 2023 through Q4 2025.
- Approximately $31M of advanced payment credited against outstanding invoices and future delivery of ~3M doses.
- Updated delivery schedule allows potential delivery of vaccine through end of 2029.
- Commonwealth granted remedies for missed deliveries, regulatory approval failures, or notification lapses.
- No additional cash payments required for future doses under the amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924129823/0001104659-24-129823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924129823/tm2431398d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-129823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer